Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2011 2012 A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy. Medivation, Inc Program Director / Principal Investigator
2. 2010 2012 A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients with Advanced Solid Tumors and Lymphomas. Ascenta Therapeutics, Inc Co-Investigator
3. 2010 2012 The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, Phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versus in: CAMN107B2301 The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, Phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versu Novartis Co-Investigator
4. 2010 2012 An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inh GSK2118436 in Combo with the MEK Inh GSK1120212 in Subjects w/ BRAF Mutant Metastatic Melanoma GlaxoSmithKline Co-Investigator
5. 2010 2012 A Phase I Study of LY2875358 in Patients with Advanced Cancer in: I4C-MC-JTBA; A Phase 1 Study of LY2875358 in Patients with Advanced Cancer Eli Lilly And Company. Co-Investigator
6. 2010 2012 A Phase II Study of BMS-754807 Combined with Letrozole in ER-Positive Breast Cancer Subjects with Acquired Resistance to Aromatase Inhibitors Bristol-Myers Squibb Pharmaceutical. Co-Investigator
7. 2010 2012 Pilot Study of CS-1008 in Combination with FOLFIRI in Subjects with Metastatic Colorectal Cancer Who Have Failed First-Line Treatment. Daiichi Sankyo Pharma Development Co-Investigator
8. 2010 2012 A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of Recmage-A3 + AS15 ASCI as Adjuvant Therapy in Patients with MAGE-A3 Positive Resected Stage III Melanoma GlaxoSmithKline Co-Investigator
9. 2010 2012 Merck Onconet MK-4827 011 A Phase I Dose Escalation Study of MK-4827 in Combination with Pegylated Liposomal Doxorubicin (Doxil TM or CaelyxTM). Merck & Co., Inc Co-Investigator
10. 2009 2012 A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma - Translational Budget Novartis Co-Investigator
11. 2009 2012 Phase I/II Study of Dasatinib/Bevacizumab in Recurrent GBM in: N0872-(BMS) Phase I/II Study of Dasatinib/Bevacizumab in recurrent GBM Bristol-Myers Squibb Pharmaceutical Co-Investigator
12. 2009 2012 A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) vs Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study in: CA182034, A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) vs Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study. Bristol-Myers Squibb Pharmaceutical Co-Investigator
13. 2009 2012 H3E-US-S130, Phase III Pemetrexed + Carboplatin Followed by Pemetrexed vs. Paclitaxel + Carboplatin + Bevacizumab Followed by Bevacizumab in Advances NSCLC with Non-squamous Histology Eli Lilly And Company Co-Investigator
14. 2009 2012 RC08CC- Use of Calcium & Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: Phase II Double-Blind Placebo Controlled Study Bristol-Myers Squibb Pharmaceutical. Co-Investigator
15. 2006 2012 Klee-Jenkins Utility of Serum and Tissue Biomarkers for Predicting Response to Androgen Deprivation Therapy in the Population of Men with Rising PSA Following Definitive Treatment in: SPORE in Prostate Cancer National Cancer Institute Co-Project Leader
16. 2011 A Randomized, Multi-Center, Placebo-Controlled Study of Mapatumumab ([HGS1012], A Fully-Human Monoclonal Antibody to Trail-R1) In Combination with Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma Human Genome Sciences, Inc Co-Investigator
17. 2011 A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in: Amendment #2 (Replacement - Expansion) MI-CP184 A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 MedImmune, Inc Co-Investigator
18. 2011 Merck Onconet MCR MK-0646-027 Phase I Parallel Protocol of MK-0646 + MK-2206 and MK-0646 + MK-0752 Doublets Merck & Co., Inc Co-Investigator
19. 2011 A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer. NewLink Genetics Co-Investigator
20. 2011 Medical Oncology FDF Template - Industry Written in: TH-CR-404 A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination Compared with Gemcitabine Alone in Previously Untreated Pts w/Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Threshold Pharmaceuticals. Co-Investigator
21. 2010 2011 The Oncotype DX® Colon Cancer Assay for Stage II Colon Carcinoma Genomic Health, Inc Co-Investigator
22. 2010 2011 2010EAP An Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer in: 2010EAP, An Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer BiPar Sciences Co-Investigator
23. 2009 2011 A Phase 1b Study to Assess the Safety and Pharmacokinetics of ARRY-334543 with Docetaxel in Patients with Advanced Solid Tumors Array BioPharma, Inc Co-Investigator
24. 2009 2011 Proteomics - Based Approach for Identifying Predictive Factors in Prostate Cancer Androgen Deprivation Therapy in: A Proteomics Approach for Identifying Predictive Factors to Androgen Deprivation National Cancer Institute Program Director / Principal Investigator
25. 2009 2011 Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma in: UMCC2005.145, Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma Pfizer Inc Program Director / Principal Investigator
26. 2009 2011 Medivation Budget Arm A in: CRPC2 A Multinational Phase III, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Medivation, Inc Program Director / Principal Investigator
27. 2009 2011 A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-Line Therapy in Men with Castrate Resistant Prostate Cancer in: OGX-011-10: A randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer. OncoGenex Technologies. Program Director / Principal Investigator
28. 2009 2011 A Phase 1b/2 Study of AMG 655 in Combination with Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects with Metastatic Colorectal Cancer Amgen Co-Investigator
29. 2009 2011 A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer in: REPLACEMENT - I2I-MC-JMMC A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer Eli Lilly And Company Co-Investigator
30. 2009 2011 A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Threshold Pharmaceuticals Co-Investigator
31. 2009 2011 Phase II arm of "A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer in: MCCRC - PHASE II ARM of I2I-MC-JMMC A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer Eli Lilly And Company. Co-Investigator
32. 2009 2011 TRIO 015 -Multicenter Open Label Phase II Study of Efficacy & Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type I Receptor...Ovarian Cancer. Cancer International Research Group. Co-Investigator
33. 2009 2011 Phase I Safety and Tolerability Study of Figitumumab Combined with Pegvisomant in Patients with Advanced Solid Tumors Pfizer Inc Co-Investigator
34. 2009 2011 A Phase 1 Study of PKI-587 Administered as an Intravenous Infusion to Subjects with Solid Tumors Wyeth Pharmaceuticals Co-Investigator
35. 2009 2011 Schedule A in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma Seattle Genetics, Inc. Co-Investigator
36. 2009 2011 Schedule B in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma Seattle Genetics, Inc. Co-Investigator
37. 2009 2011 Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer in: Amendment # 1 (replacement) N0937 Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer Cell Therapeutics, Inc Co-Investigator
38. 2009 2011 A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) when Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based Treat Nektar Therapeutics Co-Investigator
39. 2009 2011 A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease BioVex, Inc Co-Investigator
40. 2009 2011 A Phase III, Randomized, Parallel Group, Multi-Center Study in the Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171[RECENTIN] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone Astra Zeneca Pharmaceuticals Co-Investigator
41. 2008 2011 Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer in: Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer Breast Cancer Research Foundation Consultant
42. 2008 2011 A Phase 1/2, Multicenter, Dose Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of Th-302 in Combination with A)Gemciabine or B)Docetaxel or C) Pemetrexed in Subjects with Advanced Solid Tumors in: TH-CR-402, A Phase 1/2, Multicenter, Dose Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of Th-302 in Combination with A)Gemcitabine or B)Docetaxel or C) Pemetrexed in Subjects with Advanced Solid Tumors Threshold Pharmaceuticals Co-Investigator
43. 2010 A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy Bayer HealthCare AG Co-Investigator
44. 2010 A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer” in: 3144A2-3004-WW "A Randomized Double-blind Placebo controlled Trial of Neratinib (HKI-272) After Traztuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer" Pfizer Inc Co-Investigator
45. 2010 A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single Intravenous (IV) Dose of VB-111 in: VB111 - A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single Intravenous (IV) Dose of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer (DTC). Vascular Biogenics Ltd Co-Investigator
46. 2010 BRCA Testing A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer After Prior Platinum Containing First-Line Chemo. Abbott Laboratories Co-Investigator
47. 2010 A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Unresectable or Metastatic Melanoma in: H8K-MC-JZAO A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28 Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma Eli Lilly And Company Co-Investigator
48. 2010 A Randomized 3 arm Multicenter Phase III Study to Evaluate Efficacy & Safety of T-DM1 Combined with Pertuzumab or T-DM1 Combined. Hoffmann-La Roche Incorporated. Co-Investigator
49. 2010 A Randomized 3 arm Multicenter Phase III Study to Evaluate Efficacy & Safety of T-DM1 Combined with Pertuzumab or T-DM1 Combined Hoffmann-La Roche Incorporated. Co-Investigator
50. 2010 TRIO 014, A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER, PHASE II STUDY OF ADDING AMG 479 TO FIRST LINE CHEMOTHERAPY IN PATIENTS WITH OPTIMALLY DEBULKED ( < 1 cm ) EPITHELIAL OVARIAN CANCER Cancer International Research Group Co-Investigator
51. 2010 The PICASSO III Study in: IPM3001: A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma. The PICASSO III Study ZIOPHARM Oncology Inc Co-Investigator
52. 2010 Phase II Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors Oncolytics Co-Investigator
53. 2010 Randomized Phase II Study of Two Schedules of Pixantrone in Patients with MBC Cell Therapeutics, Inc Co-Investigator
54. 2010 REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with SCHNC in: REO 018: Phase 3 Study of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent SCCHN who have Progressed on or after Prior Platinum-Based Chemotherapy Oncolytics Co-Investigator
55. 2010 , A Randomized, Open-Label, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib versus Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST). Novartis Co-Investigator
56. 2008 2010 Phase I and Randomized phase II trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM). Bristol-Myers Squibb Pharmaceutical Co-Investigator
57. 2008 2010 Amendment #1 (Replacement) NO22068 “Phase Ib Study to evaluate the safety of combining IGF-1R Antagonist R1507 on with multiple standard chemotherapy drug treatments in Patients with Advanced Malignancies”. Roche Pharmaceuticals. Co-Investigator
58. 2009 Phase I/II Study of Dasatinib/Bevacizumab in Recurrent GBM in: N0872- (Genentech) PhaseI/II Study of Dasatinib/Bevacizumab in Recurrent GBM. Genentech Incorporated Co-Investigator
59. 2009 A phase 3, Multi-Center, Open-label, Randomized Study of Gemcitabine/Carboplatin, with or without BSI-201, in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer BiPar Co-Investigator
60. 2009 A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel Bristol-Myers Squibb Pharmaceutical. Co-Investigator
61. 2009 A Phase II Study of CBDCA, TAXOL and RAD001 in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP) in: N0871, A Phase II Study of CBDCA, TAXOL and RAD001 in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP). Novartis Co-Investigator
62. 2009 Phase I/II study of LBH589 and letrozole in post-menopausal women with basal-like (triple negative) metastatic breast cancer (NCCTG) in: N093B - Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer. Novartis Co-Investigator
63. 2007 2008 Arrayed imaging reflectometry based detection of circulatory peptides in prostate cancer CTSI Noval Clinical and Translational Methodologies Pilot Project, University of Rochester Co-Investigator
64. 2003 2006 Randomized controlled trial of osteoporosis prevention in racially diverse advanced stage prostate cancer patients Novartis Principal Investigator
65. 2002 2004 Role of thrombin-mediated angiogenesis in metastatic prostate cancer National Cancer Institute Principal Investigator
66. 1999 2002 Hypercoaguable states in advanced prostate cancer UAMS Reynold's Center on Aging Principal Investigator
67. 2001 Phase I pilot trial of the effects of parenteral estrogen therapy on the coagulation system of patients with advanced stage prostate cancer. Biomedical Research Foundation Principal Investigator
68. 2001 Study of angiogenic growth factors in advanced prostate cancer. American Cancer Society Institutional Research Grant Principal Investigator


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.